Insilico Medicine launches industry's first drug discovery and development Benchmark as a Service

Insilico Medicine has launched the industry's first Drug Discovery and Development Benchmark as a Service (BaaS), providing a standardised evaluation framework to measure AI models' real-world performance across drug discovery stages. This service offers independent assessment tailored to frontier AI and foundation models via comprehensive evaluation suites and standard API integration.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.